You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGemifloxacin
Accession NumberDB01155  (APRD00053)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionGemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Structure
Thumb
Synonyms
Factiv
Gemifloxacin mesilate
gemifloxacin mesylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Factivetablet320 mg/1oralMerus Labs International Inc.2003-04-04Not applicableUs
Factivetablet320 mg/1oralVansen Pharma Inc.2003-04-04Not applicableUs
Factivetablet320 mgoralOscient Pharmaceuticals Corporation2006-11-242009-02-19Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIOKR68Y0E4T
CAS number175463-14-6
WeightAverage: 389.3809
Monoisotopic: 389.149932358
Chemical FormulaC18H20FN5O4
InChI KeyInChIKey=ZRCVYEYHRGVLOC-HYARGMPZSA-N
InChI
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
IUPAC Name
7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassNaphthyridine carboxylic acids and derivatives
Direct ParentNaphthyridine carboxylic acids and derivatives
Alternative Parents
Substituents
  • Naphthyridine carboxylic acid
  • Fluoroquinolone
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrolidine
  • Tertiary amine
  • Oxime ether
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae.
PharmacodynamicsGemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
Mechanism of actionThe bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract. The absolute bioavailability averages approximately 71%.
Volume of distribution
  • 1.66 to 12.12 L/kg
Protein binding60-70%
Metabolism

Gemifloxacin is metabolized to a limited extent by the liver. All metabolites formed are minor (<10% of the administered oral dose); the principal ones are N-acetyl gemifloxacin, the E-isomer of gemifloxacin and the carbamyl glucuronide of gemifloxacin.

SubstrateEnzymesProduct
Gemifloxacin
Not Available
N-acetyl gemifloxacinDetails
Route of eliminationGemifloxacin and its metabolites are excreted via dual routes of excretion.Following oral administration of gemifloxacin to healthy subjects, a mean (± SD) of 61 ± 9.5% of the dose was excreted in the feces and 36 ± 9.3% in the urine as unchanged drug and metabolites. The mean (± SD) renal clearance following repeat doses of 320 mg was approximately 11.6 ± 3.9 L/hr (range 4.6-6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin.
Half life7 (± 2) hours
Clearance
  • renal cl=11.6+/- 3.9 L/hr [Healthy subjects receiving repeat doses of 320 mg orally]
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier-0.5099
Caco-2 permeable-0.5644
P-glycoprotein substrateSubstrate0.8404
P-glycoprotein inhibitor INon-inhibitor0.85
P-glycoprotein inhibitor IIInhibitor0.6012
Renal organic cation transporterNon-inhibitor0.5751
CYP450 2C9 substrateNon-substrate0.8462
CYP450 2D6 substrateNon-substrate0.7919
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateNon-inhibitor0.745
CYP450 2C9 inhibitorNon-inhibitor0.6642
CYP450 2D6 inhibitorNon-inhibitor0.809
CYP450 2C19 inhibitorNon-inhibitor0.6581
CYP450 3A4 inhibitorInhibitor0.5418
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7405
Ames testAMES toxic0.6124
CarcinogenicityNon-carcinogens0.7902
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5170 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Non-inhibitor0.6715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral320 mg/1
Tabletoral320 mg
Prices
Unit descriptionCostUnit
Factive 5 320 mg tablet Box148.08USD box
Factive 320 mg tablet28.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5633262 No1995-06-152015-06-15Us
US5776944 No1997-04-042017-04-04Us
US6262071 No1999-09-212019-09-21Us
US6331550 No1999-09-212019-09-21Us
US6340689 No1999-09-142019-09-14Us
US6455540 No1999-09-212019-09-21Us
US6723734 No1998-03-202018-03-20Us
US6803376 No1999-09-212019-09-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble at neutral pH (350 mg/mL at 37 °C, pH 7.0).Not Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.21 mg/mLALOGPS
logP-0.82ALOGPS
logP-0.92ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)5.53ChemAxon
pKa (Strongest Basic)9.53ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.35 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.74 m3·mol-1ChemAxon
Polarizability39.3 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5633262
General ReferencesNot Available
External Links
ATC CodesJ01MA15
AHFS Codes
  • 08:12.18
PDB EntriesNot Available
FDA labelDownload (139 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Gemifloxacin.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Gemifloxacin.
AmantadineAmantadine may increase the QTc-prolonging activities of Gemifloxacin.
AmiodaroneGemifloxacin may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Gemifloxacin.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Gemifloxacin.
AnagrelideGemifloxacin may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Gemifloxacin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Gemifloxacin.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.
Arsenic trioxideGemifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherGemifloxacin may increase the QTc-prolonging activities of Artemether.
AsenapineGemifloxacin may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Gemifloxacin.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Gemifloxacin.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Gemifloxacin.
BedaquilineGemifloxacin may increase the QTc-prolonging activities of Bedaquiline.
BevacizumabBevacizumab may increase the cardiotoxic activities of Gemifloxacin.
BortezomibBortezomib may increase the QTc-prolonging activities of Gemifloxacin.
BuserelinBuserelin may increase the QTc-prolonging activities of Gemifloxacin.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemifloxacin.
CeritinibGemifloxacin may increase the QTc-prolonging activities of Ceritinib.
ChloroquineChloroquine may increase the QTc-prolonging activities of Gemifloxacin.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Gemifloxacin.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Gemifloxacin.
CisaprideGemifloxacin may increase the QTc-prolonging activities of Cisapride.
CitalopramGemifloxacin may increase the QTc-prolonging activities of Citalopram.
ClarithromycinGemifloxacin may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Gemifloxacin.
ClozapineClozapine may increase the QTc-prolonging activities of Gemifloxacin.
CrizotinibGemifloxacin may increase the QTc-prolonging activities of Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Gemifloxacin.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Gemifloxacin.
DasatinibDasatinib may increase the QTc-prolonging activities of Gemifloxacin.
DegarelixDegarelix may increase the QTc-prolonging activities of Gemifloxacin.
DesfluraneDesflurane may increase the QTc-prolonging activities of Gemifloxacin.
DesipramineDesipramine may increase the QTc-prolonging activities of Gemifloxacin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Gemifloxacin.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Gemifloxacin.
DigoxinDigoxin may decrease the cardiotoxic activities of Gemifloxacin.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Gemifloxacin.
DisopyramideGemifloxacin may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.
DofetilideGemifloxacin may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Gemifloxacin.
DomperidoneGemifloxacin may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Gemifloxacin.
DronedaroneGemifloxacin may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Gemifloxacin.
EliglustatGemifloxacin may increase the QTc-prolonging activities of Eliglustat.
EribulinEribulin may increase the QTc-prolonging activities of Gemifloxacin.
ErythromycinErythromycin may increase the QTc-prolonging activities of Gemifloxacin.
EscitalopramGemifloxacin may increase the QTc-prolonging activities of Escitalopram.
EzogabineEzogabine may increase the QTc-prolonging activities of Gemifloxacin.
FamotidineFamotidine may increase the QTc-prolonging activities of Gemifloxacin.
FelbamateFelbamate may increase the QTc-prolonging activities of Gemifloxacin.
FingolimodFingolimod may increase the QTc-prolonging activities of Gemifloxacin.
FlecainideGemifloxacin may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Gemifloxacin.
FluoxetineGemifloxacin may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolGemifloxacin may increase the QTc-prolonging activities of Flupentixol.
FormoterolFormoterol may increase the QTc-prolonging activities of Gemifloxacin.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Gemifloxacin.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Gemifloxacin.
GalantamineGalantamine may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinGoserelin may increase the QTc-prolonging activities of Gemifloxacin.
GranisetronGranisetron may increase the QTc-prolonging activities of Gemifloxacin.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Gemifloxacin.
HistrelinHistrelin may increase the QTc-prolonging activities of Gemifloxacin.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Gemifloxacin.
IbandronateIbandronate may increase the QTc-prolonging activities of Gemifloxacin.
IbutilideGemifloxacin may increase the QTc-prolonging activities of Ibutilide.
IloperidoneGemifloxacin may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Gemifloxacin.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Gemifloxacin.
IndapamideIndapamide may increase the QTc-prolonging activities of Gemifloxacin.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Gemifloxacin.
IsradipineIsradipine may increase the QTc-prolonging activities of Gemifloxacin.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Gemifloxacin.
IvabradineIvabradine may increase the QTc-prolonging activities of Gemifloxacin.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Gemifloxacin.
LapatinibLapatinib may increase the QTc-prolonging activities of Gemifloxacin.
LenvatinibGemifloxacin may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Gemifloxacin.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Gemifloxacin.
LithiumLithium may increase the QTc-prolonging activities of Gemifloxacin.
LopinavirGemifloxacin may increase the QTc-prolonging activities of Lopinavir.
LumefantrineGemifloxacin may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Gemifloxacin.
MefloquineMefloquine may increase the QTc-prolonging activities of Gemifloxacin.
MethadoneMethadone may increase the QTc-prolonging activities of Gemifloxacin.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Gemifloxacin.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Gemifloxacin.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Gemifloxacin.
MifepristoneMifepristone may increase the QTc-prolonging activities of Gemifloxacin.
MirabegronMirabegron may increase the QTc-prolonging activities of Gemifloxacin.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Gemifloxacin.
MoexiprilMoexipril may increase the QTc-prolonging activities of Gemifloxacin.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Gemifloxacin.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Gemifloxacin.
NicardipineNicardipine may increase the QTc-prolonging activities of Gemifloxacin.
NilotinibGemifloxacin may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Gemifloxacin.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Gemifloxacin.
OctreotideOctreotide may increase the QTc-prolonging activities of Gemifloxacin.
OfloxacinGemifloxacin may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Gemifloxacin.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Gemifloxacin.
OndansetronOndansetron may increase the QTc-prolonging activities of Gemifloxacin.
OuabainOuabain may decrease the cardiotoxic activities of Gemifloxacin.
OxytocinOxytocin may increase the QTc-prolonging activities of Gemifloxacin.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin.
PaliperidoneGemifloxacin may increase the QTc-prolonging activities of Paliperidone.
PanobinostatGemifloxacin may increase the QTc-prolonging activities of Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Gemifloxacin.
PasireotidePasireotide may increase the QTc-prolonging activities of Gemifloxacin.
PazopanibGemifloxacin may increase the QTc-prolonging activities of Pazopanib.
PentamidinePentamidine may increase the QTc-prolonging activities of Gemifloxacin.
PerflutrenPerflutren may increase the QTc-prolonging activities of Gemifloxacin.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gemifloxacin.
PimozideGemifloxacin may increase the QTc-prolonging activities of Pimozide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Gemifloxacin.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Gemifloxacin.
ProbenecidProbenecid may decrease the excretion rate of Gemifloxacin which could result in a lower serum level and potentially a reduction in efficacy.
ProcainamideGemifloxacin may increase the QTc-prolonging activities of Procainamide.
PromazinePromazine may increase the QTc-prolonging activities of Gemifloxacin.
PromethazinePromethazine may increase the QTc-prolonging activities of Gemifloxacin.
PropafenoneGemifloxacin may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Gemifloxacin.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Gemifloxacin.
QuetiapineGemifloxacin may increase the QTc-prolonging activities of Quetiapine.
QuinidineGemifloxacin may increase the QTc-prolonging activities of Quinidine.
QuinineGemifloxacin may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Gemifloxacin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Gemifloxacin.
RisperidoneRisperidone may increase the QTc-prolonging activities of Gemifloxacin.
RitonavirRitonavir may increase the QTc-prolonging activities of Gemifloxacin.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Gemifloxacin.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Gemifloxacin.
SaquinavirGemifloxacin may increase the QTc-prolonging activities of Saquinavir.
SertralineSertraline may increase the QTc-prolonging activities of Gemifloxacin.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Gemifloxacin.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Gemifloxacin.
SorafenibSorafenib may increase the QTc-prolonging activities of Gemifloxacin.
SotalolGemifloxacin may increase the QTc-prolonging activities of Sotalol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Gemifloxacin.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Gemifloxacin.
SunitinibSunitinib may increase the QTc-prolonging activities of Gemifloxacin.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Gemifloxacin.
TelavancinGemifloxacin may increase the QTc-prolonging activities of Telavancin.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Gemifloxacin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Gemifloxacin.
TetrabenazineGemifloxacin may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineGemifloxacin may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Gemifloxacin.
TizanidineTizanidine may increase the QTc-prolonging activities of Gemifloxacin.
TolterodineTolterodine may increase the QTc-prolonging activities of Gemifloxacin.
ToremifeneGemifloxacin may increase the QTc-prolonging activities of Toremifene.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Gemifloxacin.
TrazodoneTrazodone may increase the QTc-prolonging activities of Gemifloxacin.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Gemifloxacin.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Gemifloxacin.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Gemifloxacin.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Gemifloxacin.
VandetanibGemifloxacin may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Gemifloxacin.
VemurafenibGemifloxacin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Gemifloxacin.
VilanterolVilanterol may increase the QTc-prolonging activities of Gemifloxacin.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Gemifloxacin.
VorinostatVorinostat may increase the QTc-prolonging activities of Gemifloxacin.
ZiprasidoneGemifloxacin may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolGemifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Ruiz J, Marco F, Sierra JM, Aguilar L, Garcia-Mendez E, Mensa J, Jimenez De Anta MT, Vila J: In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene. Int J Antimicrob Agents. 2003 Jul;22(1):73-6. [PubMed:12842332 ]
  4. Alkorta M, Gimenez MJ, Vicente D, Aguilar L, Perez-Trallero E: In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents. 2005 Feb;25(2):163-7. [PubMed:15664487 ]
  5. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM: Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. [PubMed:11796351 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Alkorta M, Gimenez MJ, Vicente D, Aguilar L, Perez-Trallero E: In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents. 2005 Feb;25(2):163-7. [PubMed:15664487 ]
  4. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM: Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. [PubMed:11796351 ]
  5. LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW: Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20. Epub 2007 Feb 12. [PubMed:17296740 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:26